The complement response against an oncolytic virus is species-specific in its activation pathways

Hiroaki Wakimoto, Keiro Ikeda, Tatsuya Abe, Tomotsugu Ichikawa, Fred H. Hochberg, R. Alan B Ezekowitz, Mark S. Pasternack, E. Antonio Chiocca

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

A variety of oncolytic viruses (OVs) are being tested in clinical trials for different human cancers. Although the innate immune response is critical as the first line of defense in thwarting viral infection of mammalian cells, little is known of this response in the context of OV therapy of tumors. Investigations of activities against a herpes simplex OV demonstrated that HSV-seronegative sera from rats, mice, and humans efficiently neutralize this OV in vitro. Although this neutralization is due to complement, activation of this innate host defense differs in its pathways among species routinely used in preclinical tumor trials. In rats, both natural immunoglobulins and mannan-binding lectin (MBL) activate complement against the OV, while in mice only MBL is relevant to this activation. However, in humans only natural immunoglobulins play a role in complement activity. Quantitative analyses confirm that in vivo complement depletion facilitates the initial infection of tumors by systemic OVs. Therefore, complement activation against oncolytic HSV vectors proceeds through different pathways in different species. These findings are relevant to preclinical rodent studies of OV therapy and their application to human clinical trials.

Original languageEnglish
Pages (from-to)275-282
Number of pages8
JournalMolecular Therapy
Volume5
Issue number3
DOIs
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Oncolytic Viruses
Oncolytic Virotherapy
Mannose-Binding Lectin
Complement Activation
Immunoglobulins
Neoplasms
Clinical Trials
Virus Diseases
Simplexvirus
Innate Immunity
Rodentia
Infection
Serum

Keywords

  • Complement
  • Gene therapy
  • HSV-1
  • Viral infection

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Wakimoto, H., Ikeda, K., Abe, T., Ichikawa, T., Hochberg, F. H., Ezekowitz, R. A. B., ... Chiocca, E. A. (2002). The complement response against an oncolytic virus is species-specific in its activation pathways. Molecular Therapy, 5(3), 275-282. https://doi.org/10.1006/mthe.2002.0547

The complement response against an oncolytic virus is species-specific in its activation pathways. / Wakimoto, Hiroaki; Ikeda, Keiro; Abe, Tatsuya; Ichikawa, Tomotsugu; Hochberg, Fred H.; Ezekowitz, R. Alan B; Pasternack, Mark S.; Chiocca, E. Antonio.

In: Molecular Therapy, Vol. 5, No. 3, 2002, p. 275-282.

Research output: Contribution to journalArticle

Wakimoto, H, Ikeda, K, Abe, T, Ichikawa, T, Hochberg, FH, Ezekowitz, RAB, Pasternack, MS & Chiocca, EA 2002, 'The complement response against an oncolytic virus is species-specific in its activation pathways', Molecular Therapy, vol. 5, no. 3, pp. 275-282. https://doi.org/10.1006/mthe.2002.0547
Wakimoto, Hiroaki ; Ikeda, Keiro ; Abe, Tatsuya ; Ichikawa, Tomotsugu ; Hochberg, Fred H. ; Ezekowitz, R. Alan B ; Pasternack, Mark S. ; Chiocca, E. Antonio. / The complement response against an oncolytic virus is species-specific in its activation pathways. In: Molecular Therapy. 2002 ; Vol. 5, No. 3. pp. 275-282.
@article{ee2537b1828641d8b10cbd22faeca543,
title = "The complement response against an oncolytic virus is species-specific in its activation pathways",
abstract = "A variety of oncolytic viruses (OVs) are being tested in clinical trials for different human cancers. Although the innate immune response is critical as the first line of defense in thwarting viral infection of mammalian cells, little is known of this response in the context of OV therapy of tumors. Investigations of activities against a herpes simplex OV demonstrated that HSV-seronegative sera from rats, mice, and humans efficiently neutralize this OV in vitro. Although this neutralization is due to complement, activation of this innate host defense differs in its pathways among species routinely used in preclinical tumor trials. In rats, both natural immunoglobulins and mannan-binding lectin (MBL) activate complement against the OV, while in mice only MBL is relevant to this activation. However, in humans only natural immunoglobulins play a role in complement activity. Quantitative analyses confirm that in vivo complement depletion facilitates the initial infection of tumors by systemic OVs. Therefore, complement activation against oncolytic HSV vectors proceeds through different pathways in different species. These findings are relevant to preclinical rodent studies of OV therapy and their application to human clinical trials.",
keywords = "Complement, Gene therapy, HSV-1, Viral infection",
author = "Hiroaki Wakimoto and Keiro Ikeda and Tatsuya Abe and Tomotsugu Ichikawa and Hochberg, {Fred H.} and Ezekowitz, {R. Alan B} and Pasternack, {Mark S.} and Chiocca, {E. Antonio}",
year = "2002",
doi = "10.1006/mthe.2002.0547",
language = "English",
volume = "5",
pages = "275--282",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - The complement response against an oncolytic virus is species-specific in its activation pathways

AU - Wakimoto, Hiroaki

AU - Ikeda, Keiro

AU - Abe, Tatsuya

AU - Ichikawa, Tomotsugu

AU - Hochberg, Fred H.

AU - Ezekowitz, R. Alan B

AU - Pasternack, Mark S.

AU - Chiocca, E. Antonio

PY - 2002

Y1 - 2002

N2 - A variety of oncolytic viruses (OVs) are being tested in clinical trials for different human cancers. Although the innate immune response is critical as the first line of defense in thwarting viral infection of mammalian cells, little is known of this response in the context of OV therapy of tumors. Investigations of activities against a herpes simplex OV demonstrated that HSV-seronegative sera from rats, mice, and humans efficiently neutralize this OV in vitro. Although this neutralization is due to complement, activation of this innate host defense differs in its pathways among species routinely used in preclinical tumor trials. In rats, both natural immunoglobulins and mannan-binding lectin (MBL) activate complement against the OV, while in mice only MBL is relevant to this activation. However, in humans only natural immunoglobulins play a role in complement activity. Quantitative analyses confirm that in vivo complement depletion facilitates the initial infection of tumors by systemic OVs. Therefore, complement activation against oncolytic HSV vectors proceeds through different pathways in different species. These findings are relevant to preclinical rodent studies of OV therapy and their application to human clinical trials.

AB - A variety of oncolytic viruses (OVs) are being tested in clinical trials for different human cancers. Although the innate immune response is critical as the first line of defense in thwarting viral infection of mammalian cells, little is known of this response in the context of OV therapy of tumors. Investigations of activities against a herpes simplex OV demonstrated that HSV-seronegative sera from rats, mice, and humans efficiently neutralize this OV in vitro. Although this neutralization is due to complement, activation of this innate host defense differs in its pathways among species routinely used in preclinical tumor trials. In rats, both natural immunoglobulins and mannan-binding lectin (MBL) activate complement against the OV, while in mice only MBL is relevant to this activation. However, in humans only natural immunoglobulins play a role in complement activity. Quantitative analyses confirm that in vivo complement depletion facilitates the initial infection of tumors by systemic OVs. Therefore, complement activation against oncolytic HSV vectors proceeds through different pathways in different species. These findings are relevant to preclinical rodent studies of OV therapy and their application to human clinical trials.

KW - Complement

KW - Gene therapy

KW - HSV-1

KW - Viral infection

UR - http://www.scopus.com/inward/record.url?scp=0036199737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036199737&partnerID=8YFLogxK

U2 - 10.1006/mthe.2002.0547

DO - 10.1006/mthe.2002.0547

M3 - Article

VL - 5

SP - 275

EP - 282

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 3

ER -